Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

BACKGROUND: PD-1/PD-L1 engagement and overexpression of galectin-3 (Gal-3) are critical mechanisms of tumor-induced immune suppression that contribute to immunotherapy resistance. We hypothesized that Gal-3 blockade with belapectin (GR-MD-02) plus anti-PD-1 (pembrolizumab) would enhance tumor respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Curti, Brendan D, Koguchi, Yoshinobu, Leidner, Rom S, Rolig, Annah S, Sturgill, Elizabeth R, Sun, Zhaoyu, Wu, Yaping, Rajamanickam, Venkatesh, Bernard, Brady, Hilgart-Martiszus, Ian, Fountain, Christopher B, Morris, George, Iwamoto, Noriko, Shimada, Takashi, Chang, ShuChing, Traber, Peter G, Zomer, Eliezer, Horton, J Rex, Shlevin, Harold, Redmond, William L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043038/
https://www.ncbi.nlm.nih.gov/pubmed/33837055
http://dx.doi.org/10.1136/jitc-2021-002371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043038/
https://www.ncbi.nlm.nih.gov/pubmed/33837055
http://dx.doi.org/10.1136/jitc-2021-002371

Ejemplares similares